Nelonemdaz用于接受血管内再灌注治疗的急性缺血性卒中患者:一项随机II期试验
这项在韩国7家卒中转诊中心进行的II期随机试验纳入209例前循环大动脉闭塞且症状发作8小时内接受血管内再灌注治疗的患者,按1:1:1分为安慰剂组、低剂量(2750 mg)Nelonemdaz组和高剂量(5250 mg)Nelonemdaz组。主要结局12周改良Rankin量表评分0-2分的比例在三组间无显著差异(54.1% vs 61.5% vs 63.2%,P=0.5578),未报告严重不良事件,作者认为需开展大规模III期试验。
要点
- 12周mRS 0-2分比例:安慰剂组54.1%、低剂量组61.5%、高剂量组63.2%,三组间无显著差异(P=0.5578)。
- 12周mRS有利偏移的常见比值比:安慰剂 vs 低剂量组为1.55(90%CI 0.92-2.60),安慰剂 vs 高剂量组为1.61(90%CI 0.94-2.76)。
- 未报告严重不良事件,Nelonemdaz治疗组显示达到12周mRS 0-2分的有利趋势,作者认为需开展大规模III期试验。
核心结论
- 12周mRS 0-2分比例在三组间无显著差异;Nelonemdaz治疗组显示达到该评分的有利趋势,且无严重不良事件,作者认为需开展大规模III期试验。
研究设计与样本
- II期随机试验,2016年10月29日至2020年6月1日在韩国7家卒中转诊中心纳入前循环大动脉闭塞且症状发作8小时内接受血管内再灌注治疗的患者。
- 筛查213例,209例按1:1:1计算机生成随机系统分组;最终208例纳入分析:安慰剂组70例、低剂量(2750 mg)Nelonemdaz组71例、高剂量(5250 mg)Nelonemdaz组67例。
- 主要结局为12周改良Rankin量表评分0-2分的患者比例。
主要发现
- 12周mRS 0-2分比例:安慰剂组33/61(54.1%)、低剂量组40/65(61.5%)、高剂量组36/57(63.2%),三组间无显著差异(P=0.5578)。
- 12周mRS有利偏移的常见比值比:安慰剂组 vs 低剂量组为1.55(90%CI 0.92-2.60),安慰剂组 vs 高剂量组为1.61(90%CI 0.94-2.76)。
- 未报告严重不良事件。
临床怎么用
- 作者认为Nelonemdaz治疗组显示达到12周mRS 0-2分的有利趋势且无严重不良事件,需开展大规模III期试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nelonemdaz is a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, as proven in preclinical ischemia-reperfusion studies. We aimed to evaluate the safety and efficacy of nelonemdaz in patients with acute ischemic stroke receiving endovascular reperfusion therapy. METHODS: This phase II randomized trial involved participants with large-artery occlusion in the anterior circulation at baseline who received endovascular reperfusion therapy <8 hours from symptom onset at 7 referral stroke centers in South Korea between October 29, 2016, and June 1, 2020. Two hundred thirteen patients were screened and 209 patients were randomly assigned at a 1:1:1 ratio using a computer-generated randomization system. Patients were divided into 3 groups based on the medication received-placebo, low-dose (2750 mg) nelonemdaz, and high-dose (5250 mg) nelonemdaz. The primary outcome was the proportion of patients with modified Rankin Scale scores of 0-2 at 12 weeks. RESULTS: Two hundred eight patients were assigned to the placebo (n=70), low-dose (n=71), and high-dose (n=67) groups. The groups had similar baseline characteristics. The primary outcome was achieved in 183 patients, and it did not differ among the groups (33/61 [54.1%], 40/65 [61.5%], and 36/57 [63.2%] patients; P=0.5578). The common odds ratio (90% CI) indicating a favorable shift in the modified Rankin Scale scores at 12 weeks was 1.55 (0.92-2.60) between the placebo and low-dose groups and 1.61 (0.94-2.76) between the placebo and high-dose groups. No serious adverse events were reported. CONCLUSIONS: The study arms showed no significant difference in the proportion of patients achieving modified Rankin Scale scores of 0-2 at 12 weeks. Nevertheless, nelonemdaz-treated patients showed a favorable tendency toward achieving these scores at 12 weeks, without serious adverse effects. Thus, a large-scale phase III trial is warranted. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT02831088.
引用
- Hong JM, Lee JS, Lee YB, et al. Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial. Stroke. 2022. PMID: 36065810. doi:10.1161/STROKEAHA.122.039649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。